Replicating patients' tumours to test different treatments

Date Time
Replicating patients’ tumours to test different treatments
UNIGE Researchers have developed in vitro tumour models that incorporate components of the tumour and elements of the patient’s immune system to test the effectiveness of treatments.
The spheroid includes cancer cells, endothelial cells, fibroblasts, monocytes and human T cells. Fluorescently labelled immune cells (green, monocytes; red, T cells) can infiltrate the preformed spheroid within 12 hours. Scale bar = 100 µm. © Magdalena Rausch
Every tumour is different, every patient is different. So how do we know which treatment will work best for the patient and eradicate the cancer? In order to offer a personalised treatment that best suits the case being treated, a team of scientists led by the University of Geneva (UNIGE), Switzerland, had already developed a spheroidal reproduction of tumours that integrates the tumour cells, but also their microenvironment. However, the immune system had not yet been taken into account, even though it can either be strengthened or destroyed by the treatment given to the patient. Today, the Geneva team has succeeded in integrating two types of immune cells that come directly from the patient into the spheroidal structure, making it possible to test the various possible treatments and select the most effective. These results can be read in the journal Cancers.

Related Keywords

Geneva ,Genè ,Switzerland ,Amsterdam ,Noord Holland ,Netherlands ,Patrycja Nowak Sliwinska ,Magdalena Rausch ,University Of Geneva ,Section Of Pharmaceutical Sciences ,University Hospitals Of Geneva ,Pharmaceutical Sciences ,University Hospitals ,University ,D ,Cancer Treatment ,Reproduction ,Immune Cells ,Scientists ,Professor ,Technique ,Treatment ,Testing ,Science ,Missing ,ஜிநீவ ,சுவிட்சர்லாந்து ,ஆம்ஸ்டர்டாம் ,நூற்த் ஹாலண்ட் ,நெதர்லாந்து ,ம்யாக்டேலீந ரௌஶ் ,பல்கலைக்கழகம் ஆஃப் ஜிநீவ ,பல்கலைக்கழகம் மருத்துவமனைகள் ஆஃப் ஜிநீவ ,மருந்து அறிவியல் ,பல்கலைக்கழகம் மருத்துவமனைகள் ,ட ,